The US Food and Drug Administration’s (FDA) one-year progress report for the Generic Drug Cluster – a multi-country forum on generic drugs – explains the purpose of the Cluster and key achievements made so far.
FDA releases one-year progress report for the Generic Drug Cluster
Generics/General | Posted 28/10/2022 0 Post your comment
The Generic Drug Cluster is a multi-country forum established by FDA to help improve alignment between regulatory agencies and achieve a common understanding of regulatory requirements for generic drugs. As well as aligning requirements and approaches to developing and assessing generic drugs, the Cluster aims to promote the development and availability of generic medicines worldwide.
In its one-year progress report, published at the end of July 2022, the Administration outlined progress made during the Cluster’s inaugural year. The Administration highlights the importance of collaboration between regulators in an increasingly globalized pharmaceutical market, where actions taken in one country can affect other countries.
The Administration has called for harmonization between agencies through increased transparency, which they say could help to streamline interactions between industry and regulatory agencies, ultimately speeding up patient access to generic drugs.
Unlike the International Council for Harmonisation (ICH), the Generic Drug Cluster is focused on establishing early communication between regulatory agencies in order to establish alignment proactively.
Accordingly, the Cluster organizes opportunities for collaboration and information sharing. In preparation for these meetings, FDA Office of Generic Drugs establishes procedures for topic proposals and confidentiality.
Meetings so far have focused on topics including high priority generic drug applications, rationale for approval of complex drug products, application data sharing, and comparing different regulatory approaches.
Key achievements from the first year of the Generic Drug Cluster include:
- An agreement for gathering and assessing data from participating agencies for an oncology drug
- An agreement for data gathering and combining for a mental health treatment – both potentially leading to a faster approval pathway
- Sharing of data on human testing on certain drugs – potentially increasing the pool of testing populations and accelerating time to approval for some drugs
- Starting to establish a process for sharing data integrity concerns, within a structured and secure information-sharing environment.
Looking ahead, the Cluster aims to reach scientific consensus of approval standards for generic drugs, including complex drug products, which they hope will form the basis of future ICH guidelines.
The ultimate goal of the Cluster is to facilitate the more efficient development and approval of generic drugs and to ensure similar standards worldwide. They say this will give patients access to high-quality generic drugs in a cost-effective manner.
Collaboration between regulatory authorities for biosimilars
LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.
View the latest headline article: Actualizaciones de las monografías de la Farmacopea Europea sobre productos bioterapéuticos
Browse the news in the Latin American Forum!
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.
Ver el último artículo de cabecera: Actualizaciones de las monografías de la Farmacopea Europea sobre productos bioterapéuticos
!Explore las noticias en el Foro Latinoamericano!
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website
Source: US FDA